These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35836882)

  • 41. Identification of Hub Genes Associated With Immune Infiltration and Predict Prognosis in Hepatocellular Carcinoma via Bioinformatics Approaches.
    Chen H; Wu J; Lu L; Hu Z; Li X; Huang L; Zhang X; Chen M; Qin X; Xie L
    Front Genet; 2020; 11():575762. PubMed ID: 33505422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of cell divisioncycle-associated genes and their prognostic significance in hepatocellular carcinoma.
    Wang Z; Xu J; Zhang S; Chang L
    Int J Clin Exp Pathol; 2021; 14(2):151-169. PubMed ID: 33564348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Prognostic Significance and Potential Mechanism of Ferroptosis-Related Genes in Hepatocellular Carcinoma.
    Li W; Liu J; Zhang D; Gu L; Zhao H
    Front Genet; 2022; 13():844624. PubMed ID: 35559035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.
    Zhang Y; Liu X; Liu L; Chen J; Hu Q; Shen S; Zhou Y; Chen S; Xue C; Cui G; Yu Z
    Dis Markers; 2020; 2020():2514090. PubMed ID: 32399086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
    Wang X; Xing Z; Chen H; Yang H; Wang Q; Xing T
    Front Oncol; 2022; 12():953529. PubMed ID: 36059705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma.
    Huang S; Dong C; Zhang J; Fu S; Lv Y; Wu J
    Front Mol Biosci; 2022; 9():943384. PubMed ID: 36052169
    [No Abstract]   [Full Text] [Related]  

  • 47.
    Tan Z; Chen M; Peng F; Yang P; Peng Z; Zhang Z; Li X; Zhu X; Zhang L; Zhao Y; Liu Y
    Transl Cancer Res; 2022 Aug; 11(8):2713-2732. PubMed ID: 36093522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
    Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
    Front Surg; 2022; 9():836080. PubMed ID: 35392063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. c-Myc-mediated SNRPB upregulation functions as an oncogene in hepatocellular carcinoma.
    Peng N; Li J; He J; Shi X; Huang H; Mo Y; Ye H; Wu G; Wu F; Xiang B; Zhong J; Li L; Zhu S
    Cell Biol Int; 2020 May; 44(5):1103-1111. PubMed ID: 31930637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determining the Prognostic Value of Spliceosome-Related Genes in Hepatocellular Carcinoma Patients.
    Liu J; Gu L; Zhang D; Li W
    Front Mol Biosci; 2022; 9():759792. PubMed ID: 35281269
    [No Abstract]   [Full Text] [Related]  

  • 51. Correlation Between Prognostic Biomarker
    Zhao J; Yang Z; Tu M; Meng W; Gao H; Li MD; Li L
    Front Oncol; 2021; 11():608641. PubMed ID: 34367941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression, immune infiltration and clinical significance of SPAG5 in hepatocellular carcinoma: A gene expression-based study.
    Chen W; Chen X; Li S; Ren B
    J Gene Med; 2020 Apr; 22(4):e3155. PubMed ID: 31860771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy.
    Zhao H; Chen C; Yang C; Mo S; Zhao H; Tian Y
    Pathol Res Pract; 2022 Apr; 232():153808. PubMed ID: 35217267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
    Jiang W; Wu T; Shi X; Xu J
    Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Centromere Protein F (
    Huang Y; Chen X; Wang L; Wang T; Tang X; Su X
    J Cancer; 2021; 12(10):2933-2951. PubMed ID: 33854594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma.
    Yang B; Zhao Y; Wang L; Zhao Y; Wei L; Chen D; Chen Z
    Front Oncol; 2020; 10():1695. PubMed ID: 33014843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma.
    Li R; Liu R; Zheng S; Liu W; Li H; Li D
    J Oncol; 2022; 2022():2607878. PubMed ID: 35047040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CXCL2/10/12/14 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma.
    Lin T; Zhang E; Mai PP; Zhang YZ; Chen X; Peng LS
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34085699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jiang J; Liu B; Liu R; Yang W
    Cancer Manag Res; 2021; 13():2517-2537. PubMed ID: 33758547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment.
    Zhang Y; Wei H; Fan L; Fang M; He X; Lu B; Pang Z
    Front Cell Dev Biol; 2021; 9():681372. PubMed ID: 34409028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.